MCTD may be diagnosed upon a clinical evaluation of overlap disorders, a detailed patient history, identification of characteristic findings, and specialized tests in blood that reveal high levels of antibodies to the U1 small nuclear ribonucleoprotein (anti-RNP) and high amounts of the antibodies ANA. Those who have mixed connective tissue disease such as systemic lupus erythematosus and systemic sclerosis disease lack the antibodies dsDNA and Scl70, respectively.
The treatment of MCTD is based upon the specific signs that are present in each case. Some patients with MCTD have been included and treated in previous trials of lupus, scleroderma, myositis, and rheumatoid arthritis. These observations and accumulated clinical practice by MCTD
The treatment of MCTD is based upon the specific signs that are present in each case. Some patients with MCTD have been included and treated in previous trials of lupus, scleroderma, myositis, and rheumatoid arthritis. These observations and accumulated clinical practice by MCTD